促红素α每周一次皮下注射治疗肾性贫血患者有效性和安全性的Meta分析

Efficiency and safety of weekly dosing of erythropoietin α in chronic kidney disease patients with anemia: a Meta- analysis

目的评价促红素α每周1次皮下注射治疗肾性贫血患者的有效性和安全性。方法检索PubMed、Cochrane、CNKI等数据库,收集关于促红素α每周1次与每周多次皮下注射的随机对照研究。提取资料并评价文献质量,用Rev Man 5.1.5对数据进行Meta分析。结果共纳入12项试验730例患者,Meta分析结果显示:每周1次与每周多次相比,在升高血红素、红细胞压积水平及不良事件发生率方面,促红素α实际使用剂量方面无统计学差异。结论每周1次与每周多次皮下注射促红素α在使用剂量、疗效与不良反应相似。

Objective To evaluate the efficiency and safety of once - weekly dosing of erythropoietin alfa （EPO） in chronic kidney disease （CKD） patients with anemia. Methods Different kinds of electronic databases were searched for randomized controlled trials （RCTs） of once - weekly vs twice - or thrice - weekly subcutaneous injection of erythropoietin in patients with renal anemia. Then the quality of the studies was evaluated and analysised by 5.1.5 Software. Results Twelve studies involving 730 patients were included. The results of the Meta - analysis showed that two kinds of dosing methods have no statistical differences in changes of Hb and Hct （%） , EPO - related adverse events and weekly consumption of EPO. Conclusion Once - weekly dosing has similar clinical effect, drugrelated adverse events and dose consumption.